EUVIMEDEUVIMED entdecken
Crossref

A complete oral regimen for induction therapy of patients with high‐risk APL : An oral etoposide instead of intravenous infusion for cytoreductive chemotherapy

Fei-Fei Tang iD, Wen-Bing Duan iD, Xiao-Hong Liu, Sheng-Ye Lu iD, Xiao-Su Zhao iD, Ya-Zhen Qin iD, Jin-Song Jia iD, Jing Wang iD, Li-Zhong Gong, Qian Jiang iD, Ting Zhao, Hong-Xia Shi und 3 weitere

British Journal of Haematology · 2024

DOI: 10.1111/bjh.19464 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Fei-Fei Tang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Ke…. Hauptthemen laut MEDLINE: Etoposide, Induction Chemotherapy, Leukemia, Promyelocytic, Acute. Die Arbeit nennt 24 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Peking University People's Hospital Research and Development Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There is an urgent need for an oral, efficient and safe regimen for high‐risk APL under the pandemic of COVID‐19. We retrospectively analysed 60 high‐risk APL patients. For induction therapy (IT), in addition to all‐trans retinoic acid (ATRA) and oral arsenic (RIF), 22 patients received oral etoposide (VP16) as cytotoxic chemotherapy (CC), and 38 patients received intravenous CC as historical control group. The median dose of oral VP16 was 1000 mg [interquartile rage (IQR), 650–1250]. One patient died during IT in the control group, 59 evaluable patients (100%) achieved complete haematological remission (CHR) after IT and complete molecular remission (CMR) after consolidation therapy. The median time to CHR and CMR was 36 days (33.8–44) versus 35 days (32–42; p = 0.75) and 3 months (0.8–3.5) versus 3.3 months (2.4–3.7; p = 0.58) in the oral VP16 group and in the control group. Two (9.1%) and 3 (7.9%) patients experienced molecular relapse in different group respectively. The 2‐year estimated overall survival and event‐free survival were 100% versus 94.7% ( p = 0.37) and 90.9% versus 89.5% ( p = 0.97) respectively. A completely oral, efficient and safe induction regimen including oral VP16 as cytoreductive chemotherapy combined with ATRA and RIF is more convenient to administer for patients with high‐risk APL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EtoposideInduction ChemotherapyLeukemia, Promyelocytic, AcuteHumansMaleFemaleMiddle AgedAdultAdministration, OralRetrospective StudiesInfusions, IntravenousAntineoplastic Combined Chemotherapy ProtocolsCOVID-19TretinoinSARS-CoV-2Remission InductionArsenicAged

Stichwörter der Autor:innen

acute promyelocytic leukaemiacompletely oraletoposide

Substanzen

EtoposideTretinoinArsenic

Autor:innen und Institutionen

  • Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking Univer…
  • Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China.

ORCID-Profile: Fei-Fei Tang, Wen-Bing Duan, Sheng-Ye Lu, Xiao-Su Zhao, Ya-Zhen Qin, Jin-Song Jia, Jing Wang, Qian Jiang, Hao Jiang

Förderung

  • National Key Research and Development Program of China
  • Peking University People's Hospital Research and Development Foundation

Zitieren

APA

Tang, F. F., Duan, W. B., Liu, X. H., Lu, S. Y., Zhao, X. S., Qin, Y. Z., Jia, J. S., Wang, J., Gong, L. Z., Jiang, Q., Zhao, T., Shi, H. X., Chang, Y. J., Huang, X. J., & Jiang, H. (2024). A complete oral regimen for induction therapy of patients with high‐risk APL : An oral etoposide instead of intravenous infusion for cytoreductive chemotherapy. British Journal of Haematology. https://doi.org/10.1111/bjh.19464

Vancouver

Tang FF, Duan WB, Liu XH, Lu SY, Zhao XS, Qin YZ, et al. A complete oral regimen for induction therapy of patients with high‐risk APL : An oral etoposide instead of intravenous infusion for cytoreductive chemotherapy. British Journal of Haematology. 2024. doi:10.1111/bjh.19464

BibTeX
@article{Tang2024,
  author = {Tang, Fei-Fei and Duan, Wen-Bing and Liu, Xiao-Hong and Lu, Sheng-Ye and Zhao, Xiao-Su and Qin, Ya-Zhen and Jia, Jin-Song and Wang, Jing and Gong, Li-Zhong and Jiang, Qian and Zhao, Ting and Shi, Hong-Xia and Chang, Ying-Jun and Huang, Xiao-Jun and Jiang, Hao},
  title = {A complete oral regimen for induction therapy of patients with high‐risk APL : An oral etoposide instead of intravenous infusion for cytoreductive chemotherapy},
  journal = {British Journal of Haematology},
  year = {2024},
  doi = {10.1111/bjh.19464}
}
Kostenlos starten →